Who are in the management team of Shalby?

As of March 2023, the management team of Shalby includes Vikram Shah (Chairman & Managing Director), Sushobhan Dasgupta (Vice Chairman), and several independent directors: Shyamal S Joshi, Umesh Menon, Ashok Bhatia, Tej Malhotra, Sujana Shah, and Vijay Kishanlal Kedia, along with Tushar Shah (Company Secretary & Compliance Officer).

As of March 2023, the management team of Shalby includes the following individuals:<BR><BR>1. Vikram Shah - Chairman & Managing Director<BR>2. Shyamal S Joshi - Independent Director<BR>3. Umesh Menon - Independent Director<BR>4. Ashok Bhatia - Independent Director<BR>5. Tej Malhotra - Independent Director<BR>6. Sujana Shah - Independent Director<BR>7. Tushar Shah - Company Secretary & Compliance Officer<BR>8. Sushobhan Dasgupta - Vice Chairman<BR>9. Vijay Kishanlal Kedia - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with key compliance and governance roles.

When is the next results date for Shalby?

No Upcoming Board Meetings

Has Shalby declared dividend?

Yes, Shalby Ltd. has declared a 12% dividend, amounting to ₹1.2 per share, with an ex-date of September 19, 2024. Despite recent negative returns in the short term, long-term performance shows positive trends, particularly over the last five years.

Shalby Ltd. has declared a 12% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: 19 Sep 24<BR><BR>Dividend Yield: 0.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Shalby experienced a price return of -24.69%, with no dividend return, resulting in a total return of -24.69%.<BR><BR>Over the past year, the price return was -29.77%, with a dividend return of 0.43%, leading to a total return of -29.34%.<BR><BR>In the 2-year period, the price return was 28.62%, with a dividend return of 1.50%, resulting in a total return of 30.12%.<BR><BR>For the 3-year period, Shalby had a price return of 57.96%, a dividend return of 3.50%, culminating in a total return of 61.46%.<BR><BR>In the last 4 years, the price return was 6.68%, with a dividend return of 2.54%, leading to a total return of 9.22%.<BR><BR>Finally, over the 5-year period, Shalby achieved a price return of 167.0%, a dividend return of 7.00%, resulting in a total return of 174.0%.<BR><BR>Overall, while Shalby has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last year and six months. However, the longer-term returns show a more positive trend, especially over the 5-year period.

Who are the peers of the Shalby?

Shalby's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, GPT Healthcare, KMC Speciality, Asarfi Hospital, and Chandan Healthcare. In terms of performance, Shalby has the lowest 1-year return at -28.92%, while Asarfi Hospital leads with a 110.53% return.

Peers: The peers of Shalby are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, GPT Healthcare, KMC Speciality, Asarfi Hospital, and Chandan Healthca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, GPT Healthcare, and Chandan Healthca, while Good management risk is found at Apollo Hospitals, Narayana Hrudaya, Global Health, and Asarfi Hospital, and Average management risk is present at Fortis Health., Shalby, KMC Speciality, and the rest. For Growth, Excellent growth is seen at Max Healthcare and Chandan Healthca, Good growth at Apollo Hospitals, Narayana Hrudaya, and Fortis Health., while Below Average growth is noted at Shalby, GPT Healthcare, KMC Speciality, and the rest. In terms of Capital Structure, Excellent capital structure is held by Max Healthcare, Global Health, GPT Healthcare, KMC Speciality, and Chandan Healthca, while Average capital structure is found at Apollo Hospitals, and Good capital structure is observed at Fortis Health., Shalby, and Asarfi Hospital.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Asarfi Hospital at 110.53%, while Shalby has the lowest 1-year return at -28.92%. Shalby's return is significantly lower than all peers. Additionally, the peers with negative six-month returns include Shalby, GPT Healthcare, KMC Speciality, and Apollo Hospitals.

What does Shalby do?

Shalby Ltd. is a small-cap hospital company based in India, originally incorporated in 2004 and publicly listed since 2006. As of March 2025, it reported net sales of ₹2,649 Cr and a net loss of ₹110 Cr.

Overview:<BR>Shalby Ltd. operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History:<BR>Shalby Ltd. was originally incorporated as 'Shalby Hospital Private Limited' in 2004. It transitioned to a public limited company in 2006, changing its name to 'Shalby Hospital Public Limited', then to 'Shalby Hospitals Limited', and finally to 'Shalby Limited' in 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,649 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -110 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 2,096 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 345.00<BR>- Industry P/E: 59<BR>- Dividend Yield: 0.62%<BR>- Debt Equity: 0.35<BR>- Return on Equity: 0.63%<BR>- Price to Book: 2.10<BR><BR>Contact Details:<BR>- Address: Opp Karnawati Club, Sarkhej Gandhinagar Highway Ahmedabad Gujarat : 380015<BR>- Tel: 91-79-40203000<BR>- Email: companysecretary@shalby.in<BR>- Website: http://www.shalby.org

Who are the top shareholders of the Shalby?

The top shareholder of Shalby is the Shah Family Trust, led by Dr. Vikram Shah, with a 34.73% stake. Other notable shareholders include 38 foreign institutional investors with 5.2% and First Water Fund, the largest public shareholder, at 1.77%.

The top shareholders of Shalby include the Shah Family Trust, represented by Dr. Vikram Shah, who holds the largest stake at 34.73%. The company is primarily owned by its promoters, with no pledged promoter holdings. Additionally, there are 38 foreign institutional investors (FIIs) who collectively hold 5.2% of the shares. The highest public shareholder is First Water Fund, with a holding of 1.77%. Individual investors account for 11.2% of the total shareholding.

How big is Shalby?

As of 24th July, Shalby Ltd. has a market capitalization of 2,237.00 Cr, with recent net sales of 1,086.95 Cr and a net profit of 6.22 Cr. Shareholder's funds are 1,000.37 Cr and total assets amount to 1,607.53 Cr as of March 2024.

As of 24th July, <BR><BR>Shalby Ltd. has a market capitalization of 2,237.00 Cr, categorizing it as a Small Cap company. <BR><BR>For the latest four quarters, Shalby reported Net Sales of 1,086.95 Cr and a Net Profit of 6.22 Cr. <BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 1,000.37 Cr and Total Assets of 1,607.53 Cr.

Are Shalby latest results good or bad?

Shalby's latest results show mixed performance; while net sales increased by 6.29%, profits declined significantly, with Profit Before Tax down 24.48% and Profit After Tax down 43%. Overall, the company faces considerable challenges despite some positive sales growth.

Shalby's latest financial results indicate a challenging situation for the company. While it achieved its highest quarterly net sales in the last five quarters, totaling Rs 296.43 crore, this growth of 6.29% year-on-year is significantly lower than the previous year's growth of 18.43%. <BR><BR>On the downside, both Profit Before Tax (PBT) and Profit After Tax (PAT) have seen substantial declines, with PBT decreasing by 24.48% to Rs 15.64 crore and PAT dropping by 43.0% to Rs 8.92 crore compared to the same quarter last year. Additionally, the inventory turnover ratio has reached its lowest point at 3.41 times, indicating difficulties in selling inventory, and interest costs have risen by 28.72%, which could pressure the company's financial stability.<BR><BR>Overall, while there are some positive sales trends, the significant drop in profits and rising costs suggest that Shalby is facing considerable challenges, making the latest results more negative than positive.

Is Shalby overvalued or undervalued?

As of October 8, 2025, Shalby is considered very attractive and undervalued, with a PE ratio of -2742.37, a price-to-book value of 2.76, and strong long-term returns of 89.9% and 190.67% over three and five years, respectively, despite recent underperformance compared to peers like Apollo Hospitals and Max Healthcare.

As of 8 October 2025, the valuation grade for Shalby has moved from attractive to very attractive. The company is currently considered undervalued, particularly given its extreme PE ratio of -2742.37 and a price-to-book value of 2.76. Other notable ratios include an EV to EBITDA of 23.96 and a ROCE of 4.99%. <BR><BR>In comparison to its peers, Shalby stands out with a significantly lower PE ratio than Apollo Hospitals, which has a PE of 70.05, and Max Healthcare, which is at 92.31. Despite the negative sentiment reflected in the recent stock performance, where Shalby has underperformed the Sensex over the past week, its long-term returns over three and five years show a robust growth of 89.9% and 190.67%, respectively, reinforcing its undervaluation narrative.

How has been the historical performance of Shalby?

Shalby's historical performance shows strong revenue growth, with net sales increasing to 1,086.96 Cr by Mar'25, but rising expenditures led to a decline in operating profit and profit after tax, which fell to 1.92 Cr. Additionally, cash flow from operating activities turned negative in Mar'25, indicating potential liquidity issues.

Answer:<BR>The historical performance of Shalby shows significant growth in net sales and operating income over the years, with net sales increasing from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25. Total operating income followed a similar trend, reaching 1,086.96 Cr in Mar'25, up from 804.92 Cr in Mar'23. However, total expenditure also rose, climbing from 344.48 Cr in Mar'21 to 954.35 Cr in Mar'25, which impacted the operating profit, which decreased from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. Profit before tax saw a decline from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, leading to a profit after tax of only 1.92 Cr in Mar'25 compared to 83.50 Cr in Mar'24. The earnings per share dropped significantly from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased from 1,193.54 Cr in Mar'22 to 1,703.65 Cr in Mar'25, while total liabilities also rose from 1,193.54 Cr to 1,703.65 Cr in the same period. Cash flow from operating activities turned negative in Mar'25 at -4.00 Cr, contrasting with positive cash flows in previous years.<BR><BR>Breakdown:<BR>Shalby's financial performance has shown a robust increase in net sales, which rose from 430.90 Cr in Mar'21 to 1,086.96 Cr in Mar'25, indicating strong revenue growth. Total operating income mirrored this growth, reaching 1,086.96 Cr in Mar'25. However, total expenditure surged to 954.35 Cr in Mar'25, leading to a decline in operating profit from 177.04 Cr in Mar'24 to 132.61 Cr in Mar'25. This decline was further reflected in profit before tax, which fell from 128.19 Cr in Mar'24 to 55.73 Cr in Mar'25, resulting in a profit after tax of just 1.92 Cr in Mar'25. The earnings per share also saw a drastic drop from 7.83 in Mar'24 to 0.58 in Mar'25. On the balance sheet, total assets increased significantly to 1,703.65 Cr in Mar'25, while total liabilities rose correspondingly, indicating a growing debt load. Cash flow from operating activities turned negative in Mar'25, contrasting with positive cash flows in prior years, highlighting potential liquidity challenges.

Is Shalby technically bullish or bearish?

As of December 1, 2025, the market trend has shifted to mildly bearish, supported by bearish MACD readings, Bollinger Bands, and Dow Theory, despite some daily moving averages indicating mild bullishness.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating bearish momentum, along with Bollinger Bands and KST both signaling bearish conditions. The Dow Theory also supports a mildly bearish outlook on both weekly and monthly time frames. Although daily moving averages show a mildly bullish signal, the overall technical indicators suggest a bearish sentiment prevailing in the market.

Should I buy, sell or hold Shalby?

Which are the latest news on Shalby?

Why is Shalby falling/rising?

As of 03-Dec, Shalby Ltd.'s stock price is declining, currently at 204.95, with a significant drop in profit and underperformance compared to the market. The stock has lost 16.07% over the past month, and declining institutional interest suggests a lack of confidence in its future performance.

As of 03-Dec, Shalby Ltd.'s stock price is falling, currently at 204.95, reflecting a change of -0.4 (-0.19%). The stock has been on a downward trend, having lost -3.26% over the past week and -16.07% over the past month. This decline is compounded by the fact that the stock has been falling for the last five consecutive days. <BR><BR>In terms of performance, Shalby has underperformed compared to the broader market, with a one-year return of -13.96%, while the Sensex has gained 5.27% in the same period. Additionally, the company's financial health shows concerning signs, such as a significant drop in profit after tax (PAT) by -82.36% for the nine-month period ending September, and a low return on capital employed (ROCE) of 6.10%, which is the lowest in the half-year period.<BR><BR>While there are some positive factors, such as a strong ability to service debt and healthy long-term growth in operating profit, these are overshadowed by the recent flat results and falling participation from institutional investors, who have reduced their stake by -0.57%. This decline in institutional interest may indicate a lack of confidence in the stock's future performance. <BR><BR>Overall, the combination of poor recent performance, declining institutional investment, and significant profit reductions contribute to the stock's current downward trajectory.